Halozyme Therapeutics Inc. buy Benchmark Co.
Start price
20.10.23
/
50%
€33.23
Target price
20.10.24
€47.17
Performance (%)
27.45%
Price
14:55
€42.35
Summary
This prediction is currently active. The prediction currently has a performance of 27.45%. This prediction currently runs until 20.10.24. The prediction end date can be changed by Benchmark_Co_ at any time. Benchmark_Co_ has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Halozyme Therapeutics Inc. | 7.805% | 7.805% |
iShares Core DAX® | 1.851% | 5.158% |
iShares Nasdaq 100 | 1.573% | 2.589% |
iShares Nikkei 225® | -0.412% | -2.857% |
iShares S&P 500 | 1.128% | 2.485% |
Comments by Benchmark_Co_ for this prediction
In the thread Halozyme Therapeutics Inc. diskutieren
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $50.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Stopped prediction by Benchmark_Co_ for Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc.
Start price
Target price
Perf. (%)
€36.23
16.04.24
16.04.24
€46.98
16.04.25
16.04.25
15.59%
14:55
14:55
Halozyme Therapeutics Inc.
Start price
Target price
Perf. (%)
€31.35
19.01.24
19.01.24
€45.94
19.01.25
19.01.25
35.09%
14:55
14:55